obesity, with a phase 2 trial finding that the amylin analogue petrelintide reduced body weight by up to 10.7% through week 42, according to a study published Sept. 29 in The Lancet Diabetes & Endocrinology.
Here are five things to know:
- Petrelintide uses a different mechanism. The once-weekly drug is a long-acting amylin analogue being developed for obesity treatment, distinct from incretin-based treatments.
- Participants lost up to 10.7% of their body weight. At 28 weeks, mean body weight reductions ranged from 7.9% to 9.8% across petrelintide doses, compared with 1.7% with placebo. Body weight continued to decline through week 42, with reductions of up to 10.7%.
- Nausea was the most common adverse event. It occurred among 79 (20%) of 404 participants receiving petrelintide, compared with five (6%) receiving placebo. Vomiting occurred among 12 (3%) receiving petrelintide.
- The phase 2 trial included 485 treated participants. The study was conducted at 32 sites in Poland, Romania and the U.S. among people with obesity without Type 2 diabetes.
- The study did not directly compare petrelintide with GLP-1 drugs. The trial compared petrelintide with placebo, so the findings do not establish that it causes fewer side effects or produces better outcomes than GLP-1 therapies. Zealand Pharma funded the trial.
